Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is used as a first-line treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms underlying its anticancer activity, particularly the subsequent develop...

Full description

Bibliographic Details
Main Authors: Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Tohru Ohmori, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryo Manabe, Yuki Hasebe, Hironori Sagara, Hitoshi Yoshida, Junji Tsurutani
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cells
Subjects:
drug resistance
osimertinib
third-generation epidermal growth factor receptor tyrosine kinase inhibitor
KRAS
EGFR
Online Access:https://www.mdpi.com/2073-4409/11/14/2201

Internet

https://www.mdpi.com/2073-4409/11/14/2201

Similar Items